Fairvalue-Calculator Fairvalue-Calculator
EN DE

Nuvalent, Inc (NUVL) Fair Value & Analysis

Healthcare · US · Market cap $7.2B

Price$123.44
Fair Value$76.36
Upside-38.1%
Quality95/100
Evidence: Low Range $57.27 – $95.45

Fair value as of: Jun 24, 2026

Analysis

Nuvalent, Inc (NUVL) currently trades at $123.44, while our model-based Fair Value estimate is $76.36 — implying the stock looks roughly 38.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Nuvalent, Inc (NUVL) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $76.36 versus a price of $123.44 — about −38% (overvalued). Model-based estimate, not financial advice.
What is the fair value of NUVL?
Our 21-model fair value for Nuvalent, Inc is $76.36 (as of Jun 24, 2026), built from audited fundamentals. The current price is $123.44.
What is the quality score of NUVL?
Nuvalent, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.